IMI grant for research into pulmonary administration of new Beta-lactam antibiotics
The department of Pharmaceutical Technology and Biopharmacy (Prof. Erik Frijlink) of the Groningen Research Institute of Pharmacy (GRIP) has received a 422K€ grant from EU’s Innovative Medicines Initiative (IMI). The “Inhaled Antibiotics in Bronchiectasis and Cystic Fibrosis” (iABC) project aims at the development of new antibiotics to be used in pulmonary diseases. The consortium consists of 19 partners from 7 countries. These groups combine experience and proven expertise and success in microbiology, antibiotic development, clinical trials, endpoints and patient registries. The activities in Groningen will focus on the development of formulations and devices for pulmonary administration of new Beta-lactam antibiotics.
IMI is Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. IMI is a joint undertaking between the European Union and the pharmaceutical industry association EFPIA.
Last modified: | 12 March 2015 1.04 p.m. |
More news
-
18 March 2024
VentureLab North helps researchers to develop succesful startups
It has happened to many researchers. While working, you suddenly ask yourself: would this not be incredibly useful for people outside of my own research discipline? There are many ways to share the results of your research. For example, think of a...
-
04 March 2024
A plant-based sensor
Every two weeks, UG Makers puts the spotlight on a researcher who has created something tangible, ranging from homemade measuring equipment for academic research to small or larger products that can change our daily lives. That is how UG...
-
11 December 2023
Join the 'Language and AI' community
As a part of the Jantina Tammes School, the 'Language and AI' theme is an interdisciplinary initiative that aims to encourage collaboration among academics, PhD candidates, students, and industry representatives who share a keen interest in the...